MARKET

ACTU

ACTU

Actuate Therapeutics Inc
NASDAQ
4.410
+0.090
+2.08%
After Hours: 4.410 0 0.00% 16:04 02/06 EST
OPEN
4.390
PREV CLOSE
4.320
HIGH
4.525
LOW
4.320
VOLUME
22.10K
TURNOVER
--
52 WEEK HIGH
11.99
52 WEEK LOW
4.140
MARKET CAP
102.50M
P/E (TTM)
-3.7074
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ACTU last week (0126-0130)?
Weekly Report · 5d ago
Weekly Report: what happened at ACTU last week (0119-0123)?
Weekly Report · 01/26 09:25
Actuate Therapeutics announces plans to expand clinical pipeline
TipRanks · 01/21 13:56
Actuate Therapeutics Reports Promising Elraglusib Results in Refractory Melanoma
Reuters · 01/21 13:45
ACTUATE THERAPEUTICS INC: INITIATION OF PHASE 1 PORTION OF TRIAL PLANNED IN 2H 2026
Reuters · 01/21 13:45
Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers
Barchart · 01/21 07:45
Weekly Report: what happened at ACTU last week (0112-0116)?
Weekly Report · 01/19 09:28
Actuate Therapeutics, Inc. (ACTU) Receives a Buy from Craig-Hallum
TipRanks · 01/15 14:06
More
About ACTU
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The Company is developing elraglusib, a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3b, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, which lead to tumor cell survival, growth, migration, and invasion. Its candidate products are Elraglusib Injection and Elraglusib Oral Tablet. Elraglusib is the lead drug in the portfolio and is being evaluated in a randomized Phase II trial in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Elraglusib is designed to act as a mediator of antitumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function.

Webull offers Actuate Therapeutics Inc stock information, including NASDAQ: ACTU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACTU stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACTU stock methods without spending real money on the virtual paper trading platform.